DDN: How drug discovery is moving beyond steroids
Drug Discovery News spoke with John Stone, MD MPH, Chair of the Scientific Advisory Board at Steritas, to discuss the origins and impact of the GTI. To read the full interview, click here.
APR: The Overexposure to Steroids for Asthma Patients
American Pharmaceutical Review publishes an article by John H. Stone, MD MPH, Chair of the Steritas Scientific Advisory Board. You can read the article here. Full reference: American Pharmaceutical ...
DD&D: The true cost of steroid-toxicity
John Stone, MD MPH, Chair of Steritas Scientific Board, discusses the true cost of steroid-toxicity with Drug Discovery & Development (DD&D). Read the full article here.
Pharmafocus: Opportunities to reduce steroid-toxicity and embrace new treatment options for autoimmune patients
Steritas' John Stone analyses the benefits that a quantifiable index system can have for researchers looking into steroid toxicity, and how this can allow them to work with larger sets of patient ...
JCS: An Interview With Dr John Stone, Steritas
The Journal for Clinical Studies (JCS) sat down with John Stone, MD MPH, Chair of the Steritas Scientific Board, to discuss the steroid-toxicity epidemic. Read the full interview, which begins on ...
DDW: Industry trends and predictions for 2025
Megan Thomas of Drug Discovery World (DDW) spoke with Martha Stone, CEO of Steritas, and other industry experts about their predictions for drug discovery opportunities in 2025. Read the article here.